Interviews with leading Life Sciences companies: Innophys Co.

Invented by Prof. Hiroshi Kobayashi, Department of Mechanical Engineering, Tokyo University of Science, the Muscle Suit® is becoming an indispensable device for the elderly care services as well as many other heavy lifting tasks. Venture Valuation (VV) interviewed Takashi Furukawa, CEO. Read the interview Would you like to be notified about new reports and other … Continue reading Interviews with leading Life Sciences companies: Innophys Co.

Read more

Interviews with leading Life Sciences companies: tella inc.

Leveraging its proprietary technology of culturing highly purified dendritic cells (DCs), tella is developing, as its first immunotherapeutic product, a DC-based vaccine in combination with WT1 (Wilms’ tumor gene 1) antigen for inoperable pancreatic cancer. Venture Valuation (VV) interviewed Dr. Yuichiro Yazaki, President and CEO. Read the interview

Read more

Interviews with leading Life Sciences companies: Cellestia Biotech AG

Created by two scientists at the École Politechnique Fédérale de Lausanne (EPFL) in 2014 and joined by experienced drug development and business professionals in 2015, Cellestia Biotech AG is developing oral medication along with companion diagnostics for Notch dependent hematological malignancies and solid tumors. Venture Valuation (VV) interviewed the CEO, Dr. Michael Bauer in Basel, … Continue reading Interviews with leading Life Sciences companies: Cellestia Biotech AG

Read more

Interviews with leading Life Sciences companies: Oncolys BioPharma Inc.

Co-founded with Prof. Toshiyoshi Fujiwara1, the inventor of the telomerase specific oncolytic adenovirus technology, Oncolys BioPharma is committed to make its therapeutic and diagnostic products available for patients with intractable cancers. Venture Valuation (VV) interviewed Yasunari Kashihara, Vice President, Business Development, and Kohei Hata, Deputy Director, Corporate Development Read the interview

Read more

Interviews with leading Life Sciences companies: CellSeed, Inc.

Having leverage with its proprietary cell sheet engineering platform technology1, Cellseed is going to commercialize two products for which the regenerative medicine market has hardly waited. hardly waited for Venture Valuation (VV) interviewed the CEO, Dr. Setsuko Hashimoto Read the interview

Read more

Interviews with leading Life Sciences companies: Abionic SA

Pioneering research on biomolecular diffusion in nanofluidics, Abionic has developed the abioSCOPE, an in-vitro platform performing quantitative diagnostic testing. Its first application products: abioKIT Total IgE (1 test in 5min) and abioKIT Aeroallergens (6 tests in 12 min) are now available in the POC diagnostic market in Europe, and in 2016 in the U.S. Venture … Continue reading Interviews with leading Life Sciences companies: Abionic SA

Read more